Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
218 hedge funds and large institutions have $1.32B invested in Meridian Bioscience Inc in 2022 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 67 increasing their positions, 67 reducing their positions, and 26 closing their positions.
231% more call options, than puts
Call options by funds: $7.31M | Put options by funds: $2.21M
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
73% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 26
7% more funds holding
Funds holding: 203 → 218 (+15)
2% more capital invested
Capital invested by funds: $1.29B → $1.32B (+$25.8M)
0% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
+$62.5M |
| 2 |
SGCM
Sand Grove Capital Management
London,
United Kingdom
|
+$17.3M |
| 3 |
Millennium Management
New York
|
+$10.5M |
| 4 |
E
Ergoteles
New York
|
+$9.65M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$9.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Impactive Capital
New York City,
New York
|
-$90.9M |
| 2 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
-$19.2M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$8.84M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.39M |
| 5 |
DAM
DLD Asset Management
New York
|
-$7.88M |
VIVO Hedge Fund Activity: Q4 2022 in Review
218 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q4 2022, worth a combined $1.32B — up 2% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new VIVO positions and 26 closed out — a net gain of 19 holders — while 67 added to existing stakes and 67 trimmed.
The largest buyer was Nexpoint Asset Management, opening a new position worth an estimated $62.5M. The largest seller was Impactive Capital, exiting entirely with an estimated $90.9M sold.
- 218 institutional investors held Meridian Bioscience Inc (VIVO) as of Q4 2022, up from 203 in Q3 2022.
- Funds reported $1.32B of Meridian Bioscience Inc stock for Q4 2022, up 2% quarter-over-quarter.
- 45 funds opened new Meridian Bioscience Inc positions in Q4 2022 and 26 closed out, a net change of +19 holders.
- The largest Meridian Bioscience Inc buyer in Q4 2022 was Nexpoint Asset Management, an estimated $62.5M added.
- The largest Meridian Bioscience Inc seller in Q4 2022 was Impactive Capital, an estimated $90.9M sold.
Based on aggregated 13F filings for Q4 2022.